中牧股份(600195.SH):乾元浩獲獸藥產品批准文號批件
格隆匯7月20日丨中牧股份(600195.SH)公佈,根據《獸藥管理條例》和《獸藥產品批准文號管理辦法》等有關規定,經農業農村部審查,准予公司控股子公司乾元浩生物股份有限公司(以下簡稱“乾元浩”)南京生物藥廠生產雞馬立克氏病基因缺失活疫苗(SC9-1株)。
乾元浩與山東農業大學、中崇信諾生物科技泰州有限公司、北京翎羽生物科技有限公司、中崇信諾生物製藥泰州有限公司聯合開展該產品的新獸藥註冊申報相關工作,並獲得三類新獸藥註冊證書。截至目前乾元浩用於開發該產品的研發費用為800萬元。
該產品是採用細菌人工染色體技術構建的雞馬立克氏病meq基因缺失株,代次清晰可控,具有良好的安全性和免疫保護效果,能有效保護各品系雞羣,對馬立克氏病流行毒株的感染有較強的預防能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.